Chondroitin Sulfate Protects the Liver in an Experimental Model of Extra-Hepatic Cholestasis Induced by Common Bile Duct Ligation

Molecules. 2022 Jan 20;27(3):654. doi: 10.3390/molecules27030654.

Abstract

During liver fibrogenesis, there is an imbalance between regeneration and wound healing. The current treatment is the withdrawal of the causing agent; thus, investigation of new and effective treatments is important. Studies have highlighted the action of chondroitin sulfate (CS) in different cells; thus, our aim was to analyze its effect on an experimental model of bile duct ligation (BDL). Adult Wistar rats were subjected to BDL and treated with CS for 7, 14, 21, or 28 days intraperitoneally. We performed histomorphometric analyses on Picrosirius-stained liver sections. Cell death was analyzed according to caspase-3 and cathepsin B activity and using a TUNEL assay. Regeneration was evaluated using PCNA immunohistochemistry. BDL led to increased collagen content with corresponding decreased liver parenchyma. CS treatment reduced total collagen and increased parenchyma content after 21 and 28 days. The treatment also promoted changes in the hepatic collagen type III/I ratio. Furthermore, it was observed that CS treatment reduced caspase-3 activity and the percentage of TUNEL-positive cells after 14 days and cathepsin B activity only after 28 days. The regeneration increased after 14, 21, and 28 days of CS treatment. In conclusion, our study showed a promising hepatoprotective action of CS in fibrogenesis induced by BDL.

Keywords: apoptosis; chondroitin; fibrosis; inflammation; liver; regeneration.

MeSH terms

  • Animals
  • Cholestasis / complications*
  • Chondroitin Sulfates / pharmacology*
  • Common Bile Duct / surgery*
  • Liver Diseases / drug therapy*
  • Liver Diseases / etiology
  • Liver Diseases / metabolism
  • Liver Diseases / pathology
  • Male
  • Protective Agents / pharmacology
  • Rats
  • Rats, Wistar

Substances

  • Protective Agents
  • Chondroitin Sulfates